3 completed, 1 terminated, 1 withdrawn. 5 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 5 | Completed 3, Terminated 1, Withdrawn 1 |
Follow Recurrent Melanoma: new trials by email Literature Review of Recurrent Melanoma trials Research Report on Recurrent Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery Diagnostic Microscopy, Fluorescein Sodium Injection, Laboratory Biomarker Analysis - Recurrent Melanoma, Stage IA Skin Melanoma | Not applicable | Completed | Roswell Park Cancer Institute | 10 | 2013-09-04 | 2020-08-07 |
| Lymph Node Mapping Using Indocyanine Green Solution in Diagnosing Patients With Malignant Melanoma Indocyanine green solution, Isosulfan blue (ISB), Lymphoscintigraphy with 99-technetium (99Tc) sulfur colloid (TSC) - Recurrent Melanoma | Not applicable | Completed | Stanford University | 50 | 2013-06-01 | 2017-05-24 |
| FDG-PET in Advanced Melanoma [18F]fluorodeoxyglucose, Molecular assays on biopsied tissue, positron emission tomography - Recurrent Melanoma, Stage IIIA Melanoma | Not applicable | Terminated | Vanderbilt-Ingram Cancer Center | 3 | 2012-05-01 | 2017-04-13 |
| Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma isolated limb perfusion, melphalan, quality-of-life assessment - Basal Cell Carcinoma of the Skin, Eccrine Carcinoma of the Skin | Not applicable | Withdrawn | Albert Einstein College of Medicine | 2012-04-01 | 2015-07-23 | |
| Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma tyrosinase peptide, MART-1:27-35 peptide vaccine, gp100 antigen - Recurrent Melanoma, Stage IV Melanoma | Not applicable | Completed | National Cancer Institute (NCI) | 30 | 2000-10-01 | 2013-01-25 |
Melanoma (5) · Carcinoma, Basal Cell (1) · Sarcoma (1) · Skin Neoplasms (1)
Neoplasms (5) · Neoplasms by Histologic Type (5) · Neoplasms by Site (5) · Neoplasms, Germ Cell and Embryonal (5) · Neoplasms, Nerve Tissue (5) · Neuroectodermal Tumors (5) · Neuroendocrine Tumors (5) · Nevi and Melanomas (5) · Skin Diseases (5) · Skin and Connective Tissue Diseases (5) · Skin Neoplasms (4) · Carcinoma (1) · Neoplasms, Basal Cell (1) · Neoplasms, Connective and Soft Tissue (1) · Neoplasms, Glandular and Epithelial (1)
Fluorescein (1) · Gene Expression (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1) · Immunohistochemistry (1) · Indocyanine Green (1) · Lymphoscintigraphy (1) · Melphalan (1) · Positron-Emission Tomography (1) · Tissue Array Analysis (1) · Tomography, Emission-Computed (1) · Tomography, X-Ray Computed (1) · gp100 Melanoma Antigen (1) · incomplete Freund's adjuvant (1) · iso-sulfan blue (1) · montanide ISA 51 (1)
Albert Einstein College of Medicine (1) · National Cancer Institute (NCI) (1) · Roswell Park Cancer Institute (1) · Stanford University (1) · Vanderbilt-Ingram Cancer Center (1)
United States (5)
Joseph Skitzki (1) · Katia Papalezova (1) · Ralph Greco (1) · Svetomir Markovic (1) · Tom Yankeelov, PhD (1)
P30CA013330 (1), P30CA016056 (1), P30CA068485 (1), P30CA124435 (1)